Vor Biopharma Inc. Operating Lease, Payments
Vor Biopharma Inc. (VOR) reported Operating Lease, Payments of $110.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-11
- Vor Biopharma Inc. operating lease, payments for the quarter ending 2026-06-30 was $110.00K, a 98.92% decline year-over-year.
- Vor Biopharma Inc. operating lease, payments for the quarter ending 2026-03-31 was $110.00K, a 93.48% decline year-over-year.
- Vor Biopharma Inc. operating lease, payments for the quarter ending 2025-12-31 was $110.00K, a 93.47% decline year-over-year.
- Vor Biopharma Inc. operating lease, payments for the quarter ending 2025-09-30 was $36.00K, a 97.82% decline year-over-year.
- Vor Biopharma Inc. operating lease, payments for fiscal 2025 was $12.03M, a 82.52% increase from fiscal 2024.
- Vor Biopharma Inc. operating lease, payments for fiscal 2024 was $6.59M, a 1.01% decline from fiscal 2023.
- Vor Biopharma Inc. operating lease, payments for fiscal 2023 was $6.66M, a 49.98% decline from fiscal 2022.
- Vor Biopharma Inc. operating lease, payments for fiscal 2022 was $13.31M, a 420.16% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $110.00K 10-Q · filed 2026-08-11 | $220.00K 10-Q · filed 2026-08-11 | $330.00K derived: sum of 3 quarters · filed 2026-08-11 | $366.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $110.00K 10-Q · filed 2026-05-13 | $220.00K derived: sum of 2 quarters · filed 2026-05-13 | $256.00K derived: sum of 3 quarters · filed 2026-05-13 | $10.45M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $110.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $146.00K derived: sum of 2 quarters · filed 2026-03-30 | $10.34M derived: sum of 3 quarters · filed 2026-08-11 | $12.03M 10-K · filed 2026-03-30 |
| 2025-09-30 | $36.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $10.23M derived: sum of 2 quarters · filed 2026-08-11 | $11.92M 10-Q · filed 2025-11-13 | $13.61M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $10.20M 10-Q · filed 2026-08-11 | $11.88M 10-Q · filed 2026-08-11 | $13.57M derived: sum of 3 quarters · filed 2026-08-11 | $15.22M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.69M 10-Q · filed 2026-05-13 | $3.37M derived: sum of 2 quarters · filed 2026-05-13 | $5.02M derived: sum of 3 quarters · filed 2026-05-13 | $6.64M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $3.33M derived: sum of 2 quarters · filed 2026-03-30 | $4.95M derived: sum of 3 quarters · filed 2026-03-30 | $6.59M 10-K · filed 2026-03-30 |
| 2024-09-30 | $1.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $3.27M derived: sum of 2 quarters · filed 2025-11-13 | $4.91M 10-Q · filed 2025-11-13 | $7.30M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $1.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $3.26M 10-Q · filed 2025-08-12 | $5.65M derived: sum of 3 quarters · filed 2025-08-12 | $6.60M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.64M 10-Q · filed 2025-05-14 | $4.03M derived: sum of 2 quarters · filed 2025-05-14 | $4.99M derived: sum of 3 quarters · filed 2025-05-14 | $6.75M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $3.35M derived: sum of 2 quarters · filed 2025-03-20 | $5.11M derived: sum of 3 quarters · filed 2025-03-20 | $6.66M 10-K · filed 2025-03-20 |
| 2023-09-30 | $951.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.72M derived: sum of 2 quarters · filed 2024-11-07 | $4.26M 10-Q · filed 2024-11-07 | $6.98M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $1.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $3.31M 10-Q · filed 2024-08-08 | $6.03M derived: sum of 3 quarters · filed 2024-08-08 | $8.10M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.54M 10-Q · filed 2024-05-09 | $4.26M derived: sum of 2 quarters · filed 2024-05-09 | $6.33M derived: sum of 3 quarters · filed 2024-05-09 | $14.13M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $2.72M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $4.79M derived: sum of 2 quarters · filed 2024-03-20 | $12.58M derived: sum of 3 quarters · filed 2024-03-20 | $13.31M 10-K · filed 2024-03-20 |
| 2022-09-30 | $2.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $9.87M derived: sum of 2 quarters · filed 2023-11-07 | $10.59M 10-Q · filed 2023-11-07 | $11.31M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $7.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $8.52M 10-Q · filed 2023-08-10 | $9.24M derived: sum of 3 quarters · filed 2023-08-10 | $9.94M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $727.00K 10-Q · filed 2023-05-11 | $1.45M derived: sum of 2 quarters · filed 2023-05-11 | $2.15M derived: sum of 3 quarters · filed 2023-05-11 | $2.84M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $719.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $1.42M derived: sum of 2 quarters · filed 2023-03-23 | $2.12M derived: sum of 3 quarters · filed 2023-03-23 | $2.56M 10-K · filed 2023-03-23 |
| 2021-09-30 | $699.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.40M derived: sum of 2 quarters · filed 2022-11-10 | $1.84M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $699.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.14M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $442.00K 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $703.00K 10-K · filed 2022-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |